Clinical Trial Update: A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL) [Phase 1]

View source ↗

Summary

This document reports the termination of a Phase I trial evaluating cyclophosphamide, rituximab, and lenalidomide (CR2) for relapsed/refractory chronic lymphocy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Revlimid (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Emory University | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia | Phase 1 | Status: TERMINATED